217 related articles for article (PubMed ID: 19482530)
1. Rosiglitazone.
Simon D
Prim Care Diabetes; 2009 May; 3(2):123-4. PubMed ID: 19482530
[No Abstract] [Full Text] [Related]
2. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
[No Abstract] [Full Text] [Related]
3. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
4. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
5. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
[TBL] [Abstract][Full Text] [Related]
6. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
7. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
8. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
9. Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas PC; Sarafidis PA; Lasaridis AN
J Cardiometab Syndr; 2007; 2(4):295-6. PubMed ID: 18059214
[No Abstract] [Full Text] [Related]
10. [Rosiglitazone--statistics for benefits and problems].
Hjelmesaeth J; Røislien J
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
[No Abstract] [Full Text] [Related]
11. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
12. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
13. Actos and Avandia in type 2 diabetes. Where do they fit?
Clark W
Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078
[No Abstract] [Full Text] [Related]
14. US regulators relax restrictions on rosiglitazone.
McCarthy M
BMJ; 2013 Nov; 347():f7144. PubMed ID: 24286989
[No Abstract] [Full Text] [Related]
15. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
16. Rosiglitazone: a thunderstorm from scarce and fragile data.
Mulrow CD; Cornell J; Localio AR
Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
[No Abstract] [Full Text] [Related]
17. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
18. The rosiglitazone controversy: the Indian perspective.
Mohan V; Joshi SR
J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
[No Abstract] [Full Text] [Related]
19. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
20. Rosiglitazone and cardiovascular risk.
Mannucci E; Monami M; Marchionni N
N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
[No Abstract] [Full Text] [Related]
[Next] [New Search]
